Invesco
PHAT icon

Invesco’s Phathom Pharmaceuticals PHAT Stock Holding History

Invesco’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.7M Sell
4,029,731
-292,329
-7% -$3.34M ﹤0.01% 1168
2026
Q1 		$48M Buy
4,322,060
+401,614
+10% +$5.07M ﹤0.01% 1088
2025
Q4 		$65M Buy
3,920,446
+55,475
+1% +$792K 0.01% 988
2025
Q3 		$45.5M Sell
3,864,971
-275,101
-7% -$2.84M 0.01% 1119
2025
Q2 		$39.7M Buy
4,140,072
+489,260
+13% +$2.71M 0.01% 1153
2025
Q1 		$22.9M Sell
3,650,812
-20,574
-0.6% -$125K ﹤0.01% 1369
2024
Q4 		$29.8M Sell
3,671,386
-425,376
-10% -$5.27M 0.01% 1296
2024
Q3 		$74.1M Buy
4,096,762
+953,310
+30% +$13.3M 0.01% 890
2024
Q2 		$32.4M Sell
3,143,452
-16,337
-0.5% -$168K 0.01% 1202
2024
Q1 		$33.6M Sell
3,159,789
-7,864
-0.2% -$66.8K 0.01% 1211
2023
Q4 		$28.9M Sell
3,167,653
-251,306
-7% -$2.17M 0.01% 1237
2023
Q3 		$35.5M Buy
3,418,959
+86,822
+3% +$1.19M 0.01% 1096
2023
Q2 		$47.7M Buy
3,332,137
+1,150,465
+53% +$13.3M 0.01% 965
2023
Q1 		$15.6M Sell
2,181,672
-25,977
-1% -$228K ﹤0.01% 1480
2022
Q4 		$24.8M Buy
2,207,649
+139,781
+7% +$1.44M 0.01% 1271
2022
Q3 		$22.9M Buy
2,067,868
+21,062
+1% +$201K 0.01% 1241
2022
Q2 		$17.3M Sell
2,046,806
-2,953
-0.1% -$30.4K 0.01% 1464
2022
Q1 		$27.9M Sell
2,049,759
-17,597
-0.9% -$284K 0.01% 1288
2021
Q4 		$40.7M Buy
2,067,356
+71,340
+4% +$1.68M 0.01% 1139
2021
Q3 		$64.1M Sell
1,996,016
-25,384
-1% -$844K 0.02% 956
2021
Q2 		$68.4M Sell
2,021,400
-7,531
-0.4% -$270K 0.02% 954
2021
Q1 		$76.2M Sell
2,028,931
-25,507
-1% -$1.07M 0.02% 904
2020
Q4 		$68.2M Sell
2,054,438
-25,749
-1% -$1.04M 0.02% 915
2020
Q3 		$76.3M Sell
2,080,187
-15,256
-0.7% -$528K 0.03% 746
2020
Q2 		$69M Buy
2,095,443
+19,758
+1% +$759K 0.02% 765
2020
Q1 		$53.6M Sell
2,075,685
-26,618
-1% -$890K 0.02% 767
2019
Q4 		$65.5M Buy
+2,102,303
New +$52.8M 0.02% 874

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Invesco's PHAT Position: Q2 2026 in Review

Invesco reduced its Phathom Pharmaceuticals (PHAT) stake by 6.8% in Q2 2026, selling an estimated $3.34M and leaving 4,029,731 shares worth $43.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1168.

Invesco first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $76.3M in Q3 2020. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Invesco held 4,029,731 shares of Phathom Pharmaceuticals worth $43.7M as of Q2 2026.
  • Invesco sold 292,329 Phathom Pharmaceuticals shares in Q2 2026, an estimated $3.34M.
  • Phathom Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1168 holding.
  • Invesco first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Invesco's Phathom Pharmaceuticals position peaked at $76.3M in Q3 2020.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.